EUCTR2017-000665-79-GB进行中（未招募）1 期
An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment with ACH-0144471 in Patients with PNH who Completed Clinical Study ACH471-100
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Patients must have completed treatment in study ACH471-100 and must have demonstrated a clinical benefit from ACH-0144471, in the opinion of the PI, with no significant safety or tolerability concerns.
- •2. Female participants of childbearing potential must agree to use an acceptable method of contraception (as defined in Section 5.5.4) from the date of signing the informed consent to the first day of dosing (Day 1), and must agree to use a highly effective method of contraception (as defined in Section 5.5.4) from the first day of dosing to 30 days after their last dose of study drug. Female participants of childbearing potential must also have a negative serum pregnancy test during Screening and negative urine pregnancy test on Day 1.
- •Female participants of non-childbearing potential need not employ a method of contraception.
- •3. Non-sterile male participants must agree to use a highly effective method of contraception (as defined in Section 5.5.4) with their partner(s) of childbearing potential from the first day of dosing to 90 days after their last dose of study drug.
- •Males who are surgically sterile need not employ additional contraception.
- •Males must agree not to donate sperm while enrolled in this study and for 90 days after their last dose of study drug.
- •4. Must agree to provide written informed consent.
- •5. Must be willing, at all times, to have transportation and telephone access, and to be within one hour of an emergency medical center
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have developed any clinically relevant co-morbidities while participating in ACH471-100 that would make the patient inappropriate for continuation of treatment with ACH-0144471, in the opinion of the investigator.
- •2. Have developed a clinically significant laboratory abnormality while participating in ACH471-100 that, in the opinion of the investigator, would make the patient inappropriate for the study or put the patient at undue risk.
- •3. Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or patients with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration
研究者
相似试验
进行中（未招募）
1 期
Study to test effectiveness and safety of a new drug, Ibrexafungerp in patients with fungal diseases who do not easily respond to, are resistant to or who are intolerant to, the current treatment for their disease.Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.EUCTR2017-000381-29-ATSCYNEXIS, Inc.220
已完成
3 期
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)candidiasisNL-OMON55351SCYNEXIS2
进行中（未招募）
1 期
Study to test effectiveness and safety of a new drug, Ibrexafungerp in patients with fungal diseases who do not easily respond to, are resistent to or who are intolerant to, the current treatment for their disease.Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.EUCTR2017-000381-29-DESCYNEXIS, Inc.220
进行中（未招募）
1 期
Study to test effectiveness and safety of a new drug, Ibrexafungerp in patients with fungal diseases who do not easily respond to, or who are intolerant to, the current treatment for their disease.EUCTR2017-000381-29-GBSCYNEXIS, Inc.200
进行中（未招募）
1 期
A study to look at the efficacy and safety of an investigational drug, revusiran, in the treatment of patients with Transthyretin-Mediated amyloidosis, whose disease has continued to worsen following liver transplantatioEUCTR2015-002603-29-ESAlnylam Pharmaceuticals, Inc12